Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Magnesium-rich Artificial Cerebrospinal Fluid Replacement on the Prognosis of Patients With Subarachnoid Hemorrhage

NCT04819451 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT04819451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04819451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Magnesium-rich Artificial Cerebrospinal Fluid Replacement on the Prognosis of Patients With Subarachnoid Hemorrhage
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Not applicable
Overall status
Unknown status
Start date
April 30, 2021
Completion date
February 1, 2024
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial hemorrhage